Cardiovascular Research

Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury.

Authors: K Przyklenk|||R A Kloner

Affiliations: + Expand

Abstract

1. Coronary artery reperfusion has become the treatment of choice for evolving myocardial infarction. 2. While there is no question that timely restoration of coronary blood flow is essential for the salvage of ischaemic myocardium, coronary reperfusion has also been associated with potentially deleterious consequences. Specifically, the viable tissue salvaged by reperfusion remains 'stunned'--i.e., exhibits prolonged abnormalities in contractile function--for hours to days following reflow. Furthermore, it has been suggested that reperfusion per se may lethally injure some myocytes that were only reversibly injured prior to restoration of blood flow. 3. ACE inhibitors such as captopril and enalapril have been shown to reduce indices of myocardial injury (infarct size, creatine kinase release) and enhance contractile function of stunned myocardium in experimental models of coronary occlusion followed by reperfusion. These effects of ACE inhibitors have largely been attributed to the reduction in myocardial O2-demand and increase in myocardial blood flow associated with blunting of angiotensin II formation. 4. Recent studies suggest that the effects of some ACE inhibitors--particularly captopril--may not solely be explained on the basis of ACE inhibition. In fact, sulphydryl (-SH) containing ACE inhibitors such as captopril appear to act as scavengers of oxygen-derived free radical species thought to be important in the pathogenesis of both postischaemic contractile dysfunction and ischaemia/reperfusion induced myocyte necrosis. 5. Thus, -SH containing ACE inhibitors--which both inhibit ACE and scavenge cytotoxic free radicals--may offer a suitable form of treatment for myocardial ischaemia/reperfusion injury.

---

Chemical List

Angiotensin-Converting Enzyme Inhibitors

---

Reference List

Circulation. 1986 May;73(5):1065-76|||J Am Coll Cardiol. 1986 Mar;7(3):455-63|||Circulation. 1986 Jul;74(1):1-5|||J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):722-8|||Cardiovasc Res. 1986 Jun;20(6):403-14|||Circulation. 1986 Dec;74(6):1424-33|||Circulation. 1987 Jun;75(6):1237-48|||Clin Exp Hypertens A. 1987;9(2-3):365-8|||J Cardiovasc Pharmacol. 1987;9 Suppl 2:S37-42|||Am J Cardiol. 1987 Oct 1;60(10):934-6|||J Clin Invest. 1988 Aug;82(2):476-85|||Am J Cardiol. 1969 Dec;24(6):753-65|||J Clin Invest. 1975 Oct;56(4):978-85|||Circulation. 1977 Nov;56(5):786-94|||Am J Physiol. 1978 Jun;234(6):H653-9|||Free Radic Biol Med. 1987;3(2):153-9|||Free Radic Biol Med. 1988;4(1):39-44|||Ann Intern Med. 1988 Apr;108(4):626-8|||Proc Natl Acad Sci U S A. 1988 Apr;85(8):2786-9|||Circulation. 1988 Jun;77(6 Pt 2):I30-9|||J Am Coll Cardiol. 1988 Jul;12(1):239-49|||Lab Invest. 1979 Jun;40(6):633-44|||Circulation. 1982 Jan;65(1):40-8|||Circulation. 1982 Dec;66(6):1146-9|||J Am Coll Cardiol. 1983 Apr;1(4):1047-55|||J Clin Invest. 1983 Jul;72(1):84-95|||J Am Coll Cardiol. 1983 Dec;2(6):1085-91|||Basic Res Cardiol. 1983 Sep-Oct;78(5):518-33|||Circulation. 1984 Feb;69(2):400-8|||Circ Res. 1984 Mar;54(3):277-85|||N Engl J Med. 1984 Sep 13;311(11):710-7|||N Engl J Med. 1985 Jan 17;312(3):159-63|||Am Heart J. 1985 Feb;109(2):222-8|||Circulation. 1985 May;71(5):1069-75|||Circulation. 1985 Jun;71(6):1087-92|||J Mol Cell Cardiol. 1985 Feb;17(2):145-52|||J Mol Cell Cardiol. 1985 Apr;17(4):291-306|||Circulation. 1985 Oct;72(4):915-21|||J Clin Invest. 1985 Nov;76(5):1713-9|||Circ Res. 1986 Jan;58(1):148-56|||Circulation. 1986 Mar;73(3):518-24|||Prog Cardiovasc Dis. 1986 May-Jun;28(6):449-62